Three-Drug immune cocktail takes on pancreatic cancer
NCT ID NCT05419479
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether combining three immunotherapy drugs (domvanalimab, zimberelimab, and APX005M) can safely control metastatic pancreatic cancer. The trial enrolls 46 people whose cancer has spread and standard treatments have stopped working. Researchers will monitor side effects and measure tumor shrinkage every 8 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
domvanalimab, zimberelimab, and APX005M (immunotherapy drugs)
What this could lead to
If it works, this could point toward a new treatment option that helps control metastatic pancreatic cancer by using the immune system to fight the tumor.
What could go wrong
This is an early-phase trial (phase 1/2) with only 46 participants, so results may not apply to everyone. The study is currently suspended, and immunotherapy can cause serious immune-related side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02115, United States